Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 in Refractory/Relapsed AML and MDS
NCT01520805Phase 2Withdrawn
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Cornerstone Pharmaceuticals. Planned start Jan 2016; status: withdrawn.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01520805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01520805.